The radionuclide ⁶⁷Cu is a highly attractive theranostic agent, combining β⁻ emission for radiotherapy with γ-rays suitable for SPECT imaging. However, achieving efficient and clean cyclotron-based production remains a major obstacle. In this study, we explore an alternative nuclear reaction route using triton beams on zinc targets—specifically ⁶⁸Zn(t,x)⁶⁷Cu—as part of the NUCSYS CSN4,...
The $\beta^-$-emitting radionuclide $^{47}$Sc is an attractive theranostic agent for nuclear medicine, offering both SPECT imaging capabilities and therapeutic efficacy for small tumors. However, its clinical deployment remains limited by production challenges, including insufficient radionuclidic purity, low yields for some reaction channels, and reliance on restricted infrastructure. In...
Terbium offers a unique set of four clinically relevant radionuclides, 149Tb, 152Tb, 155Tb, and 161Tb,covering a broad spectrum of nuclear medicine applications, from PET and SPECT imaging to targeted alpha and beta therapies. Their complementary decay properties make them ideal candidates for theranostic approaches, where diagnostic and therapeutic isotopes can be used in matched pairs [1]....
